Urinary levels of pro-fibrotic transglutaminase 2 (TG2) may help predict progression of chronic kidney disease

• Michelle Da Silva Lodge,

  Roles Formal analysis, Investigation, Writing – review & editing

  Affiliation Academic Nephrology Unit and Sheffield Kidney Institute, University of Sheffield Medical School, Sheffield, United Kingdom

  ⨯
• Nick Pullen,

  Roles Methodology, Writing – review & editing

  Current address: Jnana Therapeutics, Boston, MA, United States of America

  Affiliation Pfizer Global Research and Development, Cambridge, MA, United States of America

  ⨯
• Miguel Pereira,

  Roles Formal analysis, Writing – review & editing

  Affiliation Statistical Sciences and Innovation, UCB Pharma, Slough, United Kingdom

  ⨯
• Timothy S. Johnson

  Roles Methodology, Writing – original draft, Writing – review & editing

  * E-mail: t.johnson@sheffield.ac.uk

  Affiliation Academic Nephrology Unit and Sheffield Kidney Institute, University of Sheffield Medical School, Sheffield, United Kingdom

  https://orcid.org/0000-0003-2238-3463

  ⨯